Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

48 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The pharmacological treatment of bipolar disorder: the question of modern advances.
Hirschowitz J, Kolevzon A, Garakani A. Hirschowitz J, et al. Harv Rev Psychiatry. 2010 Sep-Oct;18(5):266-78. doi: 10.3109/10673229.2010.507042. Harv Rev Psychiatry. 2010. PMID: 20825264 Review.
METHODS: We conducted a MEDLINE search through 2009, and examined only English-language, randomized/controlled, placebo, or comparison studies. ...Newer agents may increase our armamentarium to some extent, but it is not clear if they represent a major advance in tr …
METHODS: We conducted a MEDLINE search through 2009, and examined only English-language, randomized/controlled, placebo, or compariso …
Neurobiology of anxiety disorders and implications for treatment.
Garakani A, Mathew SJ, Charney DS. Garakani A, et al. Mt Sinai J Med. 2006 Nov;73(7):941-9. Mt Sinai J Med. 2006. PMID: 17195879 Review.
Fear conditioning occurs when a neutral conditioned stimulus (such as a tone) is paired with an aversive, or unconditioned stimulus (such as a footshock), and then in the absence of the unconditioned stimulus, causes a conditioned fear response. ...Sev …
Fear conditioning occurs when a neutral conditioned stimulus (such as a tone) is paired with an aversive, or unconditioned sti …
The effect of doxapram on brain imaging in patients with panic disorder.
Garakani A, Buchsbaum MS, Newmark RE, Goodman C, Aaronson CJ, Martinez JM, Torosjan Y, Chu KW, Gorman JM. Garakani A, et al. Eur Neuropsychopharmacol. 2007 Oct;17(10):672-86. doi: 10.1016/j.euroneuro.2007.04.002. Epub 2007 Jun 8. Eur Neuropsychopharmacol. 2007. PMID: 17560768 Free PMC article. Clinical Trial.
Administration of doxapram hydrochloride, a respiratory stimulant, is experienced by panic disorder patients to be similar to panic attacks but has reduced emotional effect in normal volunteers, thus providing a laboratory model of panic for functional imaging. Six …
Administration of doxapram hydrochloride, a respiratory stimulant, is experienced by panic disorder patients to be similar to panic a …
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J. Garakani A, et al. Int Clin Psychopharmacol. 2008 Sep;23(5):269-75. doi: 10.1097/YIC.0b013e328301a74c. Int Clin Psychopharmacol. 2008. PMID: 18703936 Clinical Trial.
A total of 114 patients with major depressive disorder were enrolled in an 8-week treatment study. Patients were initiated on a course of fluoxetine treatment and randomized to quetiapine or placebo. ...The study indicates that quetiapine plus fluoxetine did not ach
A total of 114 patients with major depressive disorder were enrolled in an 8-week treatment study. Patients were initiated on a
Effect of medication and psychotherapy on heart rate variability in panic disorder.
Garakani A, Martinez JM, Aaronson CJ, Voustianiouk A, Kaufmann H, Gorman JM. Garakani A, et al. Depress Anxiety. 2009;26(3):251-8. doi: 10.1002/da.20533. Depress Anxiety. 2009. PMID: 18839407 Clinical Trial.
Our aim was to investigate the effects of treatment on heart rate (HR) in patients with PD through a hyperventilation challenge. ...Subjects lay supine with their heads in a plastic canopy chamber, resting for 15 min and then breathing at a rate of 30 breaths …
Our aim was to investigate the effects of treatment on heart rate (HR) in patients with PD through a hyperventilation challenge. ...S …
Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
Mathew SJ, Garakani A, Reinhard JF Jr, Oshana S, Donahue S. Mathew SJ, et al. Clin Ther. 2008 Sep;30(9):1658-66. doi: 10.1016/j.clinthera.2008.09.006. Clin Ther. 2008. PMID: 18840371 Clinical Trial.
A 1-week, single-blind placebo run-in was followed by a 28-day,open-label treatment with PRX-00023 QD in a forced-titration protocol: 40 mg (days 1-4), 80 mg (days 5-14), and 120 mg (days 15-28). ...Secondary outcomes included the baseline-to-end point change
A 1-week, single-blind placebo run-in was followed by a 28-day,open-label treatment with PRX-00023 QD in a forced-titra
Heart rate and blood pressure changes during autonomic nervous system challenge in panic disorder patients.
Martinez JM, Garakani A, Kaufmann H, Aaronson CJ, Gorman JM. Martinez JM, et al. Psychosom Med. 2010 Jun;72(5):442-9. doi: 10.1097/PSY.0b013e3181d972c2. Epub 2010 Apr 5. Psychosom Med. 2010. PMID: 20368476
OBJECTIVE: To test the hypothesis that panic disorder (PD) patients have a heightened or deregulated autonomic nervous system at rest and during autonomic challenge compared with healthy controls (HC); and to test a second hypothesis that severity of illness differe …
OBJECTIVE: To test the hypothesis that panic disorder (PD) patients have a heightened or deregulated autonomic nervous system at rest …
Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.
Krystal JH, Mathew SJ, D'Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Krystal JH, et al. CNS Drugs. 2010 Aug;24(8):669-93. doi: 10.2165/11533230-000000000-00000. CNS Drugs. 2010. PMID: 20658799 Review.
The research in this area is at a relatively early stage, as there are no drugs acting at mGluRs that have been approved for the treatment of any psychiatric disorder. ...Further, the genes coding for mGluRs are implicated in the risk for a growing number of psychia …
The research in this area is at a relatively early stage, as there are no drugs acting at mGluRs that have been approved for the trea …
Proinflammatory and "resiliency" proteins in the CSF of patients with major depression.
Martinez JM, Garakani A, Yehuda R, Gorman JM. Martinez JM, et al. Depress Anxiety. 2012 Jan;29(1):32-8. doi: 10.1002/da.20876. Epub 2011 Sep 2. Depress Anxiety. 2012. PMID: 21898706
BACKGROUND: A number of studies have shown that elevated levels of inflammatory cytokines may promote depression and suicidal ideation and that neuroprotective peptides may decrease the response to stress and depression. ...METHODS: Eighteen patients with major depression …
BACKGROUND: A number of studies have shown that elevated levels of inflammatory cytokines may promote depression and suicidal ideatio …
Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment.
Garakani A, Martinez JM, Yehuda R, Gorman JM. Garakani A, et al. J Affect Disord. 2013 Apr 5;146(2):262-5. doi: 10.1016/j.jad.2012.06.037. Epub 2012 Jul 25. J Affect Disord. 2013. PMID: 22840611
Patients with MDD underwent 8 weeks of treatment with the antidepressant venlafaxine and then had a repeat LP post treatment. ...LIMITATIONS: There was a small sample size, age discordance between patients and controls, lack of a follow-up LP in controls, abs …
Patients with MDD underwent 8 weeks of treatment with the antidepressant venlafaxine and then had a repeat LP post treatment. ...LIMI …
48 results
Jump to page
Feedback